NRBO סך נכסי הפעילות העסקית NeuroBo Pharmaceuticals Inc
The development of drugs for metabolic disorders is not subject to GDP influence or seasonal fluctuations, confirming the resilience of NeuroBo Pharmaceuticals (NRBO). This chart illustrates the asset's market value reaching 24.26, alongside strict compliance with FDA bio-waste disposal regulations. The business relies on the search for advanced methods of regenerating damaged nerves to assist individuals with severe diabetes complications.
פילוחים אנליטיים ודוחות נתונים של חברת NeuroBo (NRBO)
Total assets represent the aggregate value of the company's resources, reverse-calculated via ROA to assess the fundamental basis, which allows an investor to determine business resilience to shocks through the analysis of asset and resource growth; for NeuroBo Pharmaceuticals (NRBO), this resilience is particularly high due to the non-cyclical nature of developing drugs for metabolic pathologies and the independence of R&D from macroeconomic fluctuations.